• 11/11/2024

AstraZeneca Core EPS Rises 25%; Maintains Revenue Outlook

Wall Street Journal

AstraZeneca said its second-quarter core earnings per share rose to $2.15, and reiterated its 2023 forceast for revenue to increase by a low-to-mid single-digit percentage.

https://www.wsj.com/articles/astrazeneca-2q-net-profit-rose-but-missed-forecasts-backs-guidance-e1cdfd3c